NCT05286801 2026-04-13
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
National Cancer Institute (NCI)
Alliance Foundation Trials, LLC.
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
M.D. Anderson Cancer Center
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche